Post 1 2024
-
Plenary session explores the potent, dynamic terrain of artificial intelligence applications in oncology
Researchers explored the potential of artificial intelligence for accelerating evidence generation, advancing disparities research, and improving trial design during a plenary session on the final day of the AACR Annual Meeting 2024.
-
Study findings highlight potential of novel immunotherapy strategies
Sundar Jagannath, MD, and other presenters discussed emerging results on immunotherapy approaches beyond immune checkpoint inhibitors during a clinical trials plenary session.
-
Clinical trials evaluate novel immune checkpoint inhibitor combinations
Deborah J. Wong, MD, PhD, and other speakers presented findings on novel combinations of immune checkpoint inhibitors during a clinical trials plenary session.
-
Seminal research on the underpinnings of metastasis presented in plenary session
Sarah-Maria Fendt, PhD, and other researchers tackled the evolution of the genome, microenvironment, and host through metastasis during a plenary session.
-
Presidential Address charts the long, winding road to engineering T cells
AACR Immediate Past President Philip D. Greenberg, MD, FAACR, explored his own continuing experience with engineering T cells to eradicate tumors during a lecture at the Annual Meeting.
-
Pezcoller Foundation-AACR award recipient details work on telomeres
Titia de Lange, PhD, FAACR, was recognized with the Pezcoller Foundation-AACR International Award for Extraordinary Achievement in Cancer Research and presented a lecture on telomeres and cancer, including tumor suppression and genome instability.